Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

Video

In Partnership With:

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Willem Overwijk, PhD, associate professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Cancer vaccines that aim to induce a T cell or B-cell response must first go through the innate immune system. The innate immune system must be activated, and pick up the antigens that are provided by the vaccine, explains Overwijk. Vaccine adjuvants can stimulate the innate immune cells, to help prime and activate the adaptive immune cells.

The innate immune cells themselves, which support and promote cancer growth, can also be directly inhibited with therapeutics, says Overwijk. Lenalidomide is an example of a drug that utilizes this mechanism of action. Lenalidomide blocks cytokines that support multiple myeloma cells in the bone marrow. By blocking the production of those cytokines from innate immune cells, tumor growth can be slowed down and become more sensitive to other types of cancer treatment, says Overwijk.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer